drugset
drugset / Trial / NCT03341884

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

NCT03341884 ↗

Phase 1 Completed 29 enrolled Genentech, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1 study evaluating the pharmacokinetics, tolerability and safety of a single dose of ipatasertib in participants with mild, moderate or severe hepatic impairment compared to healthy participants.

Timeline

Start
2017-11-09
Primary completion
2018-06-26
Completion
2018-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipatasertib Small molecule 100 mg Oral

Indications

liver disorder